Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs
February 06 2020 - 9:30AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to
announce the new appointment of Russell I. Thomson PhD, FRSC to the
position of Nymox Vice President of Quality and Regulatory
Affairs. Dr Thomson is an authority in the field of Quality
Assurance and Control in the chemical and pharmaceutical
industries.
Dr. Thomson is a Fellow of the Royal Society of
Chemistry (UK), a Chartered Chemist and Chairman of the Royal
Society of Chemistry Qualified Persons Assessors Panel. He
has worked in the pharmaceutical industry in positions including
Head of Quality and Director of QA and Regulatory Affairs, and as
Consultant Qualified Person at numerous large and small drug
manufacturing facilities in the EU and the US for over 20
years. Dr. Thomson was a Chartered Scientist with The Science
Council (UK) from 2004-2010 and Corporate Member of the South
African Chemical Institute from 1980-1999. He received his PhD in
Chemistry from the University of South Africa.
Dr. Paul Averback, CEO of Nymox said,
"Management and the Board are extremely pleased to have Dr. Thomson
take on the position of VP of Quality and Regulatory
Affairs. This is a key management position at a crucial time
in the Company’s history as we are soon to submit both an
NDA in the U.S. and an MAA in Europe. Dr.
Thomson will work closely with Dr. Mark Staples, Nymox VP
for Chemistry Manufacturing and Controls, to jointly assure that
Nymox's manufacturing standards are fully compliant with all US and
international regulations. As VP of Quality and Regulatory Affairs,
Dr. Thomson is responsible for all activities related to Quality
Control and Quality Assurance of Nymox's manufacturing in the US
and the EU. Russell is an authority on implementation of
Quality Assurance for manufacturing in this sector
and brings to Nymox his vast knowledge and practical
experience. His appointment to VP of Quality and Regulatory
affairs is great news for the Nymox team and our collaborators."
For more information please
contact info@nymox.com or 800-936-9669. Forward
Looking Statements To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2018, and its Quarterly Reports.
For Further Information Contact:
Erik DanielsenNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024